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Abstract
Background
Many studies have measured the intensity of end of life care. However, no summary of the
measures used in the field is currently available.
Objectives
To summarise features, characteristics of use and reported validity of measures used for
evaluating intensity of end of life care.
Methods
This was a systematic review according to PRISMA guidelines. We performed a compre-
hensive literature search in Ovid Medline, Embase, The Cochrane Library of Systematic
Reviews and reference lists published between 1990-2014. Two reviewers independently
screened titles, abstracts, full texts and extracted data. Studies were eligible if they used a
measure of end of life care intensity, defined as all quantifiable measures describing the
type and intensity of medical care administered during the last year of life.
Results
A total of 58 of 1590 potentially eligible studies met our inclusion criteria and were included.
The most commonly reported measures were hospitalizations (n = 44), intensive care unit
admissions (n = 39) and chemotherapy use (n = 27). Studies measured intensity of care in
different timeframes ranging from 48 hours to 12 months. The majority of studies were con-
ducted in cancer patients (n = 31). Only 4 studies included information on validation of the
measures used. None evaluated construct validity, while 3 studies considered criterion and
1 study reported both content and criterion validity.
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Conclusions
This review provides a synthesis to aid in choosing intensity of end of life care measures
based on their previous use but simultaneously highlights the crucial need for more valida-
tion studies and consensus in the field.
Introduction
As the world’s population ages, research on end of life care is increasingly important. Health-
care expenditures in the last year of life are, on average, five times higher than in other years
[1]. Health services near the end of life are often responsible for much of the increased costs
since many patients die in acute care settings [1, 2]. Efforts to improve end of life care require
accurate measurement of the care provided.
Healthcare costs at the end of life are directly related to the intensity of care. Intensity of end
of life care is usually highest in hospital settings. Evidence suggests that in the days just before
death patients commonly receive invasive or life prolonging procedures. For example, studies
have shown about half of patients at the end of life receive mechanical ventilation, undergo
chemotherapy, and a quarter receive cardio pulmonary resuscitation (CPR) [3–6]. Although
these practices are common, they do not always align with patients’ preferences.
Nearly 40% of patients die in acute care hospitals [7]. Yet studies report between 45%-86%
of patients at the end of life say they would prefer to die at home [7–10]. End of life treatments
may be more influenced by factors like local practice patterns and number of hospital beds
than by patients’ preference [10–13]. Consideration of costs and clinical outcomes are key to
understanding the quality of end of life care, however, appropriateness of care is ultimately
judged by patients’ preferences.
Previous studies have highlighted issues that arise when measuring end of life care [14, 15].
Defining the end phase of life can be ambiguous and terms are often used differently between
clinical settings, healthcare professionals and researchers. There are many different illness tra-
jectories for dying people, and there is no accurate clinical indicator to predict time of death
[16, 17]. As a result definitions for the end of life phase vary considerably. Furthermore, in
order to measure intensity of care at the end of life, it is essential to first define what is meant
by both intensity and end of life care. Intensity of care attempts to identify high levels of utiliza-
tion and not to merely quantify healthcare use. End of life care generally considers all health
care administered in a distinct timeframe before death. It is often used interchangeably with
various other terms such as palliative care, hospice care, or terminal care [18]. This lack of
agreement presents methodological challenges when conducting and comparing end of life re-
search [19, 20].
Despite these challenges many studies have measured the intensity of care at the end of life
[11, 21–23]. However, researchers disagree on the standards of measurement, and no overview
of the measures used in the field is currently available [21]. A plethora of measures have been
used in previous research—most commonly high usage of hospitals, the number of physician
visits, CPR, mechanical ventilation, tracheostomy, and chemotherapy near the end of life [21,
24, 25].
Studies of the intensity of end of life care require reliable and valid measures that work in
different care settings, populations and diseases. However, it is currently unclear what tools
have adequate validity and should be recommended for measuring intensity of end of life care.
In this systematic review, we provide a comprehensive overview of the measures of intensity of
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end of life care that are currently used in published original research. We summarize their fea-
tures (i.e., type of measures) and describe characteristics of their use (i.e., population, time-
frame) and reported validity.
Methods
The methods to identify, select, and critically appraise the relevant studies in this systematic re-
view are reported according to the PRISMA (preferred reporting items for systematic reviews
and meta-analyses) guidelines [26].
Definition
We defined measures of intensity of end of life care as all quantifiable measures describing the
type and intensity of medical care administered during the last year of life. We included the fol-
lowing categories of care: hospitalizations (acute hospital, intensive care unit [ICU]; emergency
department [ED]); potentially life-sustaining invasive procedures which include a range of
treatments administering complex, invasive methods to prolong a person's life (e.g., resuscita-
tion, intubation, and mechanical ventilation, artificial feeding, dialysis); and potentially life-
prolonging treatments (e.g., surgery, chemotherapy, radiation, medical imaging, transfusions).
Literature search and eligibility criteria
Studies were included in this systematic review based on the following criteria: (1) used a mea-
sure that met our definition and (2) explicitly stated they were measuring intensity of end of
life care. We included cohort studies (prospective and retrospective), case-control studies, and
randomised-controlled trials. We included all studies that used the term intensity or a syno-
nym (intensive, aggressive, extensive) or that indicated they were quantifying higher or in-
creased levels (frequencies, rates) of end of life care. We searched for studies reporting
measures of intensity of end of life care in adults aged 18 or older. We excluded studies on chil-
dren and patients with mental illness because these population groups have different care
needs and thus may require different measures of intensity of care. We also excluded studies
that: (1) did not include a clearly defined end of life timeframe (e.g. measured within 30 days
before death); (2) reported exclusively on cost; (3) included exclusively clinical palliative care;
(4) evaluated only outpatient settings; (5) were case reports; or (6) were published before 1990.
OVID Medline, EMBASE, and the Cochrane Database for Systematic Reviews were
searched to identify studies from 1 January 1990 up to 29 January 2014. We used the following
key words: end of life care; last year of life; last months of life; terminal care; terminally ill; criti-
cally ill; palliative care; treatment intensity; intensity of care; intensity of treatment; aggres-
siveness of care; amount of care; health services utilization. A specific search strategy was
developed for each database. No language restrictions were applied. We identified additional
studies by hand-searching the reference lists of included studies. Appendix 1 provides detailed
information on search terms.
Two reviewers (X.L. and M.M.) independently screened titles, abstracts, and full texts. Dis-
agreements about inclusion and exclusion were resolved through consensus with a third re-
viewer (K.C.).
Data extraction and quality assessment
We extracted the following information for each study: author; year of publication; country;
aim; design; details on the study populations (disease, age, and gender); setting (e.g., emergency
department, intensive care unit); and a description of the measure. When studies used more
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than one measure, or included more than one population (multiple comparison groups), we
only extracted data on the measures that met our inclusion criteria.
We developed an individualized assessment checklist that included both validation of indi-
vidual measures and criteria for quality of methods used. We extracted data on the validity of
measures [27, 28], including face and content validity (measure covers the domains considered
to be important, assessment is based on the subjective views of experts); criterion validity (mea-
sure correlates with another instrument that measures similar aspects, preferably a reference
standard or one that is widely used and accepted in the field); and construct validity (measure
conforms with the results using other established scales or different groups of patients).
We rated the quality of evidence as: “good” (reported measure validity, measure was used in
other studies, well-described study design, thorough assessment of potential sources of bias
well documented strengths and limitations); “moderate” (no reported measure validity and
met three or more other criteria); and “low” (no reported measure validity and met less than
three other criteria). We contacted developers of measures and sought additional information
on validity of measures. Two reviewers (X.L. and M.M.) independently extracted data from
each included study.
Results
Identification of eligible studies
We identified 1590 potentially eligible studies and included 58 studies that met our inclusion
criteria and described measures of intensity of end of life care in the last year of life (Fig 1).
Characteristics of studies
Characteristics of included studies are provided in Table 1. The majority of studies were in
populations aged 65 years and older. Only four studies were gender-specific (i.e. males alone).
Three were prospective cohort studies, 53 retrospective cohort studies and two were random-
ized controlled trials. Almost all studies relied on administrative data. Study aims were hetero-
geneous. Twenty-four studies looked explicitly at the measures of intensity of care. The
remaining studies did not have intensity of care as a primary aim but met our definition
(Table 1). They evaluated health care utilization/care patterns at the end of life (n = 17), varia-
tion of end of life care across different settings, populations and time trends (n = 14), or evalu-
ated quality of end of life care (n = 3). Studies measured intensity of life care over different
timeframes ranging from hours to months, in disease-specific populations (including cancer,
heart failure, other chronic disease [e.g., respiratory diseases, end stage renal disease], trauma,
multiple diseases [e.g., hip fracture, COPD, colorectal cancer and acute myocardial infraction])
and non-disease-specific populations (Table 1).
Types of measures
We organized measures into three key domains of end of life care: hospitalizations, life-sustain-
ing invasive procedures and life-prolonging treatments. The majority of studies used more
than one measure. Table 2 provides an overview of the measures by domain with descriptions
of each measure.
Hospitalizations. Measures focusing on hospitalizations were most widely reported
(n = 44). They were used most commonly in cancer patients (n = 22), with fewer studies in
groups with other illnesses. Intensity of end of life care was reported as number of hospitaliza-
tions (count, mean, median, percentage, standard deviation [SD], categorical yes/no), number
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of re-admissions (count), and hospital length of stay (LOS: count of days, months, median, cat-
egorical cut-off e.g.>1,>2,>14 days).
We identified 39 studies that measured intensity of ICU use in the last months of life, as
ICU admissions (count, median interquartile range [IQR], rate, %, SD) or ICU LOS (count of
days, median, categorical cut-off e.g. 0, 1,2 days). Emergency department (ED) admissions
were reported in 24 studies, as ED visits (mean, percentage, rate) or ED admissions (with and
without hospital admission) and cut-offs of ED visits in the last month of life (0, 1, 2,3).
Potentially life-sustaining invasive procedures. Compared with hospitalizations, studies
measuring intensity of life-sustaining treatments were less numerous. The most commonly re-
ported life-sustaining treatments were intubation/mechanical ventilation (n = 17), measured as
receipt of intubation/mechanical ventilation (yes/no). Other measures included feeding tube
placement (n = 10), dialysis (n = 10), CPR (n = 9), and tracheostomy (n = 6). These measures
were applied in both disease and non-disease specific populations, but were more widely used
in cancer patients.
Potentially life-prolonging treatments. Chemotherapy was the most frequently reported
life-prolonging treatment (n = 27), described as chemotherapy use (mean, median, range, stan-
dard deviation [SD]), average number of cycles and regimens within the last 3–6 months, or
last 7–30 days for a range of cancer types (e.g., prostate, lung, breast, colorectal, gastrointesti-
nal, colorectal). Eight studies evaluated intensity of surgical procedures at the end of life (e.g.
general, gynaecologic, orthopaedic, thoracic, and urologic or neurosurgical interventions). One
study developed a surgical intensity score defined as the proportion of decedents who received
a surgical procedure during the last year of life (e.g., any surgery that involved incision, exci-
sion, manipulation, suturing of tissue). Ten studies measured receipt of radiotherapy in the last
14–30 days of life. Other less frequently reported measures were number of blood transfusions,
and medical imaging.
The vast majority of studies measuring intensity of life-prolonging treatments reported re-
sults using more than one measure (e.g. ICU, ED, and chemotherapy).
Summary score. Two studies reported results based on an intensity of end of life care sum-
mary scores (Table 1). Earle et al., (2005) combined six measures (use of chemotherapy,>1
ED visit,>1 hospital admission,>14 days in hospital,>1 ICU admission, or death in hospital)
with higher scores (range 0–6) indicating more intensive end of life care. This score was
adopted in other studies (Tang et al., 2009). Lin et al., (2009) combined seven measures (ICU
admission, ICU LOS, intubation and mechanical ventilation, haemodialysis, tracheostomy,
gastrostomy) also with higher scores (range from -2.08 to 3.12) indicating more intensive end
of care.
Validity. Four studies involved a panel of experts to assess content validity (n = 3) or crite-
rion validity (n = 1). One study reported both on content and criterion validity. No study re-
ported on construct validity. Earle et al., (2008) explored validity of their intensity of end of life
care measures by correlating them with measures of family members’ satisfaction with quality
of care near the end of life. The results showed (statistically non-significant) trends toward less
satisfaction with care when chemotherapy was administered two weeks before death, death oc-
curred in an acute care setting, or there was no or only a short (3 day) hospice stay. Sato and
colleagues (2008) assessed content validity and inter-rater reliability using a team of physicians,
palliative care doctors and research nurses. Earle and colleagues (2005) used an expert panel of
health providers to assess the validity of measures such as chemotherapy, ED/ICU admission,
hospitalization, hospice use. Barnato et al., (2009) assessed criterion validity by comparing
Fig 1. Identification of eligible articles onmeasures of intensity of end of life care.
doi:10.1371/journal.pone.0123764.g001
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Table 1. Characteristics of included studies.
Aim All studies(%) (n = 58)
Intensity of care 24 (41.4)
Health care utilization 17 (29.3)
Time trends in end of life care 14 (24.1)
Quality of end of life care 3 (5.2)
Year
1990–1994 2 (3.4)
1995–1999 1 (1.7)
2000–2004 4 (6.9)
2005–2009 21 (36.2)
2010–2014 30 (51.7)
Country
Asia 4 (6.9)
Australia 1 (1.7)
Europe 8 (13.8)
Northern America 45 (77.6)
Study design
Prospective cohort study 3 (5.2)
Retrospective cohort study 53 (91.3)
Randomised controlled trials 2 (3.4)
Validity
Criterion validity 3 (5.2)
Content and criterion validity 1 (1.7)
Summary score
Includeda 2 (3.4)
Minimum age for inclusion (years)
18+ 4 (6.9)
60+ 30 (51.7)
Otherb 24 (41.4)
Disease
Cancer 31 (53.4)
Chronic diseasesc 5 (8.6)
Heart failure 2 (3.4)
Trauma 1 (1.7)
Multiple diseasesd 3 (5.2)
Non-disease speciﬁc 16 (27.6)
End of life timeframe
1 month 23 (39.7)
2 months 1 (1.7)
3 months 1 (1.7)
6 months 18 (31.0)
12 months 15 (25.9)
Number of measures reported in each study
Single measuree 7 (12.0)
More than one measure (range 2–46) 51 (87.9)
(Continued)
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Pennsylvania Health Care Cost Containment Council discharge data (PHC4) intensity of end
of life care measures with measures used in the Dartmouth Atlas of Health Care. The study re-
ported correlations for six measures of the PHC4 (ICU admission, ICU LOS, intubation and
mechanical ventilation, tracheostomy, gastrostomy tube placement, haemodialysis) and the
four Dartmouth Atlas measures (inpatient reimbursement, hospital days, ICU days, medical
doctor visits) in two populations (decedents and patients with a high probability of dying on
hospital admissions).
Quality of evidence
We considered the quality of evidence to be good for 9 (15. 5%) studies, moderate for 46
(79.3%) studies and low for 3 (5.1%) studies (Table 1). The most common reason for down-
grading the quality of evidence was the lack of validity of measures. There were few studies
which we rated as good because the measures were repeatedly adopted in other studies. This
was particularly the case with measures developed by Earle et al., (2004) and Earle et al.,
(2005).
Discussion
Summary of main findings
To the best of our knowledge, this is the first systematic review of measures used for evaluating
intensity of end of life care. We assessed studies measuring hospitalizations, life-sustaining in-
vasive procedures and life-prolonging treatments in the last 12 months of life. Aims, popula-
tions studied, definitions of intensity of end of life care and measures used were heterogeneous
across studies. The number of intensity of end of life care studies grew over the last decade with
over 50% of the studies included published within the last five years. Our findings show that in-
tensity of end of life care is most commonly evaluated using a combination of measures, in-
cluding two summary score measures. This review also highlights an important deficit in
health services research of end of life care. Measures of intensity of end of life care, although
widely used in health services research, lack validation and general agreement by experts in the
field. Overall, we consider the evidence to be of moderate quality. It could be argued that the
lack of prospective studies reflects the difficulty of conducting research with people who are ap-
proaching death [29].
Table 1. (Continued)
Aim All studies(%) (n = 58)
Quality of evidence
Good 9 (15.5)
Moderate 46 (79.3)
Low 3 (5.1)
aOne study included six individual measures (chemotherapy use, >1 ED visit, >1 hospital admission, >14
days in hospital, >1 ICU admission, or death in hospital), and one study included seven individual
measures (ICU admission, ICU LOS, intubation and mechanical ventilation, haemodialysis, tracheostomy,
gastrostomy).
bReported age as mean and median.
cChronic diseases (e.g., respiratory diseases, end—stage renal disease).
dHip fracture, COPD, colorectal cancer and acute myocardial infraction.
eIncluded only one measure (e.g., radiotherapy use, chemotherapy use).
doi:10.1371/journal.pone.0123764.t001
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Table 2. Summary of intensity of end of life care measures from included studies.
Category of care Description of measures N References
No. of hospitalizations(count, mean, median, %, rate, SD,
categorical yes/no)
44 [11, 12, 23, 24, 40–79]
Number of hospital re-admissions (count)
Admitted to the hospital (yes/no)
Hospital LOS (days, months, median, categorical cut—off e.g.>1
>2, >14 days)
ICU admission (count, median, [IQR], rate, %, SD, yes/no) 39 [11–13, 21–24, 41, 42, 44, 45, 47, 52–59, 65–68, 72–
86]
Hospitalizations Any ICU admission (count)
ICU LOS (days, mean, median, categorical yes/no, categorical cut-
off e.g., 0, 1, 2)
ICU admission during hospital stay (yes/no)
Terminal ICU admission (rate, %)
ED visits (mean, %, rate, categorical yes/no, categorical cut off
of ED visits)
24 [24, 40, 41, 47–51, 53–55, 57, 65–67, 71, 74–76, 79,
80, 84, 85, 87]
ED with and without hospital admission (categorical yes/no)
Intubation/mechanical ventilation (categorical yes/no, rate, %) 17 [13, 21–23, 45, 51, 52, 56, 58, 66, 68, 72, 77, 82, 83,
86, 87]
Ventilator days (count of days)
Life-sustaining
procedures
CPR (median, mean, categorical yes/no, %) 9 [21, 23, 45, 48, 51, 58, 66, 68, 72]
Feeding tube placement (rate, categorical yes/no, %) 10 [13, 21, 23, 45, 51, 58, 68, 72, 82, 83]
Tracheostomy (rate, categorical yes/no, %) 6 [21, 22, 45, 72, 82, 83]
Dialysis (rate, categorical yes/no, %) 10 [21, 22, 51, 72, 78, 82, 83, 86–88]
Chemotherapy (count, categorical yes/no, %) 27 [24, 43, 47–51, 53–55, 57, 58, 62, 65–68, 72–76, 80,
84, 85, 87, 89]
Intravenous chemotherapy (median, range, mean, SD)
Oral chemotherapy (median, range, mean, SD)
Average number of chemotherapy cycles* (%)
Average number of chemotherapy regimens* (%)
Life-prolonging
treatments
Blood transfusion (%, categorical yes/no) 2 [72, 87]
Receipt of radiotherapy (categorical yes/no, %) 10 [41, 43, 48, 49, 51, 53, 76, 80, 87, 90]
Radiotherapy days (count of days)
Underwent medical imaging (categorical yes/no) 5 [13, 48, 56, 72, 87]
Surgical interventions (diagnostic, curative, elective, palliative
(yes/no)
8 [11, 13, 41, 43, 45, 46, 49, 51]
Surgical admissions (mean, yes/no, %)
Abbreviations: SD, standard deviation; IQR, interquartile range; ED, emergency department; CPR, cardiopulmonary resuscitation; ICU, intensive care unit;
LOS, length of stay.
*Chemotherapy regimens include treatment plans (e.g. type of drugs, instructions on when the drug should be taken) whereas chemotherapy cycles
include the time of chemotherapy treatment and the break before the next chemotherapy.
doi:10.1371/journal.pone.0123764.t002
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Strengths and weaknesses of the systematic review
This systematic review was based on a comprehensive literature search that resulted in the in-
clusion of 58 studies that reported on a variety of intensity of end of life care measures. We col-
lected an extensive list of details on the studies and the measures that researchers used. The
greatest strength of this systematic review is that it provides a unique and detail-rich overview
of measures of intensity of end of life care used in a wide variety of settings.
There is no agreement on the end of life timeframe, which ranges in the literature from
hours to months [16]. The World Health Organization [30] has a published a commonly used
definition for palliative care, but it includes neither timeframe, nor terminology for intensity of
care, nor a definition of end of life care. Previous research also revealed no general agreement
on the best interval or measures for identifying end of life care [31]. As a result, we may have
missed some potentially relevant studies on end of life care because they did not fall within our
strict definition. We also focused only on services, and did not include other settings like outpa-
tient clinics, hospice or home care. We included all studies that met our definition but were un-
able to account for differences in definition. We recognize that our definition may not be
entirely consistent with other definitions of intensity of end of life care. We do not suggest that
ours is the best definition but regard it as good working definition that represents a broad set of
health services research designed to evaluate the intensity of end of life care.
Challenges in measuring the intensity of end of life care
Our findings should be interpreted carefully, since many of the studies we included did not
focus on measuring intensity of end of life care alone. Less than half of the studies we reviewed
were based on an explicit definition or primarily aimed to study intensity of end of life care.
Many measures included in this review were used to evaluate health care utilization more gen-
erally. However, the measures often overlapped despite differences in objectives. Thus it re-
mains unclear if measures developed specifically to assess intensity of care are necessary.
Health services utilization measures answer questions about volume of care [32] while mea-
sures of intensity of care tend to be more disease specific. For example, measures of aggres-
siveness of care (e.g. frequent ED visits or hospitalizations, long inpatient LOS) are nearly
exclusively used in cancer populations to assess poor quality of end of life care [24]. The pauci-
ty of validation studies makes distinguishing between measures and their specific uses difficult.
These two sets of measures originate from differences in the purposes of studies (e.g., a health
service perspective vs. a clinical perspective). Both sets of measures are potentially useful and a
better understanding of which measures should be used in which settings would be instrumen-
tal to guiding health service research in the future.
Many of the examined studies actually repeatedly utilize a single measure set, those mea-
sures developed by Earle, C.C., et al. (2004). These measures have subsequently been adopted
for various uses, including by the American Society of Clinical Oncology's QOPI (quality on-
cology practice initiative) measure set (http://www.asco.org/). The repeated use of this measure
set reflects the influence of these measures, whether or not they have been formally validated.
Our study shows that hospitalization rates at the end of life are high, regardless of the speci-
fications of the measure selected. High number of hospitalizations at the end of life may be re-
lated to lack of structure and availability of homecare services. Previous studies suggest that
increased end of life homecare services will reduce the demand for acute care services at the
end of life as well as improve the quality of life of these patients [24, 33, 34]. Furthermore, treat-
ment delivered at the end of life may also be related to the region of care. [1, 35]. Unfortunately,
given the mass of papers from North America and small numbers from other regions it was
not possible to adequately examine results by region. There was a different pattern of care for
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cancer patients than for the non-disease specific group. Measures developed for cancer patients
are well documented and over represented in the literature. However, the majority of these
studies reuses data primarily collected for administrative purposes thus restricting any poten-
tial influence to a non-measurable unsystematic bias.
These measures generally examined the last month of life, when cancer patients are most
likely to be hospitalized. The trajectory to death is easier to identify for cancer patients than the
trajectory for patients with other diseases, and this may account for the difference. Measures
designed for cancer care may not be appropriate for other disease, and more research on end of
life measures should be conducted on populations with other diseases like heart failure. How-
ever, measures developed for general populations may not be specific enough to identify areas
for quality improvement. Measures also vary between countries, perhaps due to the wide range
of health policies, and organizational structures, across countries.
Most research on intensity of end of life care is based on retrospective cohort studies that
use administrative data because it is only possible to determine the exact period before death
retrospectively [15, 20]. Thus, the most readily available sources of healthcare use are adminis-
trative datasets. Most studies retrospectively assessed the care received by patients in the time
frame before death, but one study identified patients who were entering the terminal phase of
disease, and whose probability of death was high, and then prospectively observed patient care
forward in time [21, 36]. Each approach has advantages and disadvantages. Measures based on
treatments given to patients with a high probability of dying may accurately identify end of life
patients and be less prone to bias [37, 38]. Researchers argue that, in order for the results to be
valid, the care of end of life patients must be captured prospectively [19]. But the higher quality
of retrospective data may produce results more useful for monitoring end of life care across
providers, geographic areas, demographic groups, and time periods [37].
An analysis of the qualitative literature on the intensity of end of life care was beyond the
scope of this study. Several qualitative tools have been developed to measure different aspects
of end of life, including quality of life, physical symptom control, emotional and cognitive
symptoms, spirituality, grief and bereavement, satisfaction and quality of care, and caregiver
well-being [39].
Conclusions
There is no consensus on the definition for intensity of end of life care. The associated mea-
sures are seldom validated and often used for varying aims, in differing populations and most
commonly in combinations of more than one at a time. Definitions, methods, and strategies all
vary across studies and countries. The choice and assessment of measures of intensity of care at
the end of life should be based on the aim of the study although which measure suits specific
aims best remains unclear. This review is the first to attempt to identify measures used specifi-
cally for evaluating intensity of end of life care. It provides a synthesis for choosing measures
based on their previous use but also highlights the crucial need for more validation studies.
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